title: [Comment to P. J. Olbert et al., page 164].
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinikum der RWTH Aachen, Pauwelstrasse 30, Aachen. aheidenreich@ukaachen.de
authors.forename: A
authors.initials: A
authors.lastname: Heidenreich
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D014408:Biomarkers, Tumor / Q000097:blood; D018849:Controlled Clinical Trials as Topic; D018450:Disease Progression; D000077143:Docetaxel; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D019233:Retreatment; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000633:toxicity*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen